CDC- BRFSS – ACBS 2019 Adult Prevalence Table 8

Table 8: Estimated percent using inhaled short acting beta agonists among adults1 with current2 asthma status by state/territory – BRFSS Asthma Call-back Survey, United States, 2019.
State/Territory Current
Sample
size±
% SE§ 95% CI
Arizona 244 55.9 6.0 (44.1 – 67.7)
California 261 51.1 4.1 (43.1 – 59.1)
Connecticut 272 55.1 5.1 (45.1 – 65.1)
Florida 473 41.9 4.3 (33.5 – 50.3)
Hawaii 193 38.4 4.7 (29.2 – 47.6)
Illinois 159 52.2 4.7 (43.0 – 61.4)
Indiana 227 53.4 4.4 (44.8 – 62.0)
Iowa 239 46.9 4.3 (38.5 – 55.3)
Kansas 279 50.2 4.3 (41.8 – 58.6)
Kentucky 290 56.9 4.8 (47.5 – 66.3)
Maine 486 49.4 4.3 (41.0 – 57.8)
Massachusetts 250 50.9 4.3 (42.5 – 59.3)
Michigan 492 59.0 3.3 (52.5 – 65.5)
Minnesota 475 54.8 2.8 (49.3 – 60.3)
Missouri 212 58.6 5.0 (48.8 – 68.4)
Montana 227 52.9 4.3 (44.5 – 61.3)
Nebraska 416 51.2 3.9 (43.6 – 58.8)
New Hampshire 288 55.5 4.0 (47.7 – 63.3)
New Mexico 181 70.5 5.4 (59.9 – 81.1)
Ohio 395 49.0 3.8 (41.6 – 56.4)
Oregon 269 52.6 3.9 (45.0 – 60.2)
Pennsylvania 221 51.4 4.4 (42.8 – 60.0)
Rhode Island 181 52.3 6.3 (40.0 – 64.6)
Texas 265 49.7 5.5 (38.9 – 60.5)
Utah 403 53.7 3.3 (47.2 – 60.2)
Vermont 239 50.9 5.2 (40.7 – 61.1)
Wisconsin 209 53.9 5.0 (44.1 – 63.7)
27 States / Area 7,846 51.8 1.2 (49.4 – 54.2)
Median 52.3
Range 38.4-70.5

1 Aged ≥ 18 years

2 “Yes” response to “Do you still have asthma?”

± Sample size for adults with current asthma, excludes “DK/Refused”

§ Standard error

Confidence interval

Link for Summary Data Quality Report: https://www.cdc.gov/brfss/acbs/2019/pdf/sdq_report_acbs_19-508.pdf